Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Rating of “Reduce” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been given an average recommendation of “Reduce” by the nine research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a hold recommendation to the company.

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th.

Bayer Aktiengesellschaft Stock Down 0.4 %

Shares of Bayer Aktiengesellschaft stock opened at $8.22 on Friday. Bayer Aktiengesellschaft has a 52-week low of $6.82 and a 52-week high of $11.96. The company has a 50 day moving average of $7.73 and a 200 day moving average of $7.50. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $32.30 billion, a P/E ratio of -9.45 and a beta of 1.08.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. The company had revenue of $12 billion for the quarter. As a group, research analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.